Showing results (181-190 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|July 5, 2016
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trialColleen Delaney, Filippo Milano, Laura Cicconi, et al.
The Lancet. Haematology|July 5, 2016
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, A John Ashcroft, David A Cairns, et al.
The Lancet. Haematology|April 30, 2021
COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 yearJenneke Leentjens, Thijs F van Haaps, Pieter F Wessels, et al.
The Lancet. Haematology|August 27, 2021
Multimodal intervention for preventing peripheral intravenous catheter failure in adults (PREBACP): a multicentre, cluster-randomised, controlled trialIan Blanco-Mavillard, Joan Ernest de Pedro-Gómez, Miguel Ángel Rodríguez-Calero, et al.
The Lancet. Haematology|August 27, 2021
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trialAnna-Katharina Zoellner, Michael Unterhalt, Stephan Stilgenbauer, et al.
The Lancet. Haematology|August 29, 2025
Cost-effective targets for anaemia reduction in 191 countries: a modelling studyRobin Blythe, Natalie Carvalho, Jacinta Holloway-Brown, et al.
The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
The Lancet. Haematology|September 2, 2022
Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 yearsGlenn F Pierce, Megan Adediran, Saliou Diop, et al.
The Lancet. Haematology|September 9, 2022
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort studySara Ghorashian, Elad Jacoby, Barbara De Moerloose, et al.
Pageof 73